Proteins and Peptides
25 February 2014
FDA approves Myalept to treat rare metabolic disease24 February 2014
Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder20 February 2014
BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome19 February 2014
FDA Accepts Filing of the Medicines Company’s New Drug Application for Intravenous Antibiotic Oritavancin With Priority Review18 February 2014
Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease18 February 2014
Bayer ’s Long-Acting Recombinant Factor VIII Demonstrated Effective Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial15 February 2014
BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome13 February 2014
Synageva BioPharma(TM) Highlights SBC-103 Data at the Lysosomal Disease Network (LDN) WORLD Symposium(TM)12 February 2014
BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia11 February 2014
BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)10 February 2014
Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule10 February 2014
Protalex Announces Interim Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients5 February 2014
Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain29 January 2014
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mL25 January 2014
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes24 January 2014
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EUNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports